THE APEX TIMES
Dividend calendars take center stage as UnitedHealth and other S&P names declare higher payouts
A roundup of recent dividend declarations highlighted UnitedHealth, Donaldson, Lowe’s, ePlus and Toronto-Dominion Bank, reflecting investor demand for income streams during a volatile macro backdrop.
Wall Street’s focus on dividend reliability is resurfacing this week after a Zacks Equity Research roundup pointed to several well-known companies that have either raised or most recently declared quarterly dividends. The blog framed the move as a response to inflation concerns and geopolitical uncertainty, conditions that can make investors look for steadier cash returns rather than purely growth-oriented plays.
UnitedHealth Group (UNH) declared a quarterly dividend of $2.32 per share, payable June 23, after recording the dividend on June 15. The company’s dividend history also shows the prior quarterly amount at $2.21, paid in March, indicating a step-up for the second quarter. Zacks also cited UNH’s dividend yield at about 2.3% and put its payout ratio at 54% of earnings. (The payout ratio is the share of earnings a company distributes as dividends.)
Industrial supplier Donaldson (DCI) declared a dividend of 32.0 cents per share, payable June 30, with shareholders of record on June 15. Donaldson’s investor relations release said the 32.0-cent dividend was up 6.7% from the prior 30.0-cent quarter, and Zacks echoed the higher-income focus by citing a dividend yield around 1.4% and a payout ratio of 32%.
Home improvement retailer Lowe’s (LOW) declared a quarterly cash dividend of $1.25 per share, payable Aug. 5, with shareholders of record as of July 22. Lowe’s said this represented a 4% increase versus its prior $1.20 dividend. In the same Zacks roundup, Lowe’s was cited with a dividend yield of roughly 2.3% and a payout ratio of 39%.
Technology solutions provider ePlus (PLUS) declared a quarterly cash dividend of $0.27 per common share, payable June 30, to shareholders of record on June 17, according to the company. Zacks highlighted ePlus alongside the other dividend-paying stocks, citing a dividend yield of about 1.2% and a payout ratio of 22%. The company did not spell out a year-over-year or quarter-over-quarter percentage increase in the declaration itself in the materials reviewed.
Toronto-Dominion Bank (TD) was also included in the Zacks dividend roundup. TD’s own statement declared a dividend of C$1.12 per common share for the quarter ending July 31, payable on and after July 31 to shareholders of record on July 10, with amounts disclosed in Canadian dollars. Zacks, meanwhile, presented TD in its roundup with a higher-level snapshot that emphasized the dividend income profile and payout discipline.
Taken together, the declarations point to a broader theme: dividend announcements can offer a concrete announcement of management confidence and cash generation during periods when investors are unsure about economic direction. For companies, steady dividends also help reinforce shareholder return commitments and can support valuation narratives that are less dependent on near-term earnings volatility. Still, the dividend story is inherently time-bound, and investors typically track whether payout levels remain sustainable as medical costs, housing activity, industrial demand, technology spending and credit conditions evolve.
Caveat: Zacks’ blog provides a consistent framework for comparing dividend-paying companies using metrics like dividend yield and payout ratio, but those measures can depend on timing and underlying earnings assumptions. In addition, dividend declarations can change if boards revise capital allocation plans, and the roundup does not provide full financial details beyond each company’s dividend snapshot, leaving broader sustainability questions to later earnings and guidance updates. What is clear from the declarations reviewed is the immediate availability of the next dividend payments and record dates, which are often what investors act on first. Next, watch for updated earnings commentary on cash flow, payout coverage, and any changes to capital return plans as each company reports results and sets the next quarter’s dividend cadence.
Why It Matters
- Dividend announcements can shift market attention toward cash-return visibility during periods when inflation and geopolitical risk complicate growth forecasts.
- Companies that raise or maintain dividends may gain interest from investors targeting income, especially when payout ratios appear contained relative to earnings.
- For healthcare and consumer-facing businesses, near-term dividend decisions can serve as a proxy for management’s view of cash flow stability, even though it does not guarantee future payout growth.
- The next step for investors is to compare these dividend snapshots against each firm’s upcoming earnings coverage of dividends and any capital allocation updates.
Sources
- (Yahoo Finance redirect to Zacks blog)
- Zacks blog: dividend roundup with specific dividend amounts and metrics
- UnitedHealth dividend history (UNH)
- Donaldson investor relations: increases quarterly cash dividend 6.7% (DCI)
- Lowe’s corporate newsroom: announces increase in quarterly cash dividend to $1.25 per share
- ePlus press release (via Nasdaq): quarterly cash dividend of $0.27 payable June 30 (PLUS)
- TD media room: TD Bank Group declares dividends (all amounts in Canadian dollars) (TD)
- Image
Key Facts
- Zacks highlighted five dividend-paying stocks: UnitedHealth (UNH), Donaldson (DCI), Lowe’s (LOW), ePlus (PLUS) and Toronto-Dominion Bank (TD).
- UnitedHealth declared a $2.32 quarterly dividend payable June 23, after recording the dividend on June 15.
- Donaldson declared a 32.0-cent quarterly dividend payable June 30, an increase from the prior 30.0-cent quarter.
- Lowe’s declared a $1.25 quarterly dividend payable Aug. 5, described by the company as a 4% increase from $1.20.
- ePlus declared a $0.27 quarterly dividend payable June 30 to shareholders of record on June 17.
- TD declared a C$1.12 quarterly dividend per common share for the quarter ending July 31, payable on and after July 31 to shareholders of record on July 10.
Healthcare Related
Eli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipeline
The company agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based consideration.
Eli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansion
The acquisition, reported as worth as much as $2.88 billion, adds another chapter to Lilly’s ongoing buy-or-build approach as biotech rivals also compete for late-stage assets and platform-like capabilities.
Johnson & Johnson schedules investor call for third-quarter results on Oct. 13
The company will hold an investor conference call at 8:30 a.m. Eastern Time to discuss its third-quarter performance, according to a notice posted by Yahoo Finance.
Pfizer reaches confidential settlement in Depo-Provera litigation over alleged meningioma risk
The agreement covers multiple federal lawsuits involving its Depo-Provera contraceptive and claims of an increased risk of intracranial meningioma, according to a report.
Moderna takes August’s S&P 500 win as biotech momentum lifts MRNA shares
A Yahoo Finance review of monthly performance found Moderna leading the S&P 500 in August, rising about 158%, while Edison International finished last, down roughly 27%.
Eli Lilly CEO David Ricks frames its $25B spending push as a long-term bet beyond obesity
In a CNBC interview, Eli Lilly’s chief executive said the company’s recent deal and investment activity is aimed at extending the durability of its obesity franchise and using related technologies to target other diseases through the 2030s, while acknowledging that not every bet will succeed.
Eli Lilly investors weigh valuation after fresh FDA nod, analyst models show mixed picture
A recent market note points to an estimated 30% upside from discounted cash flow modeling, even as other valuation checks look less clear-cut after a new Food and Drug Administration approval.
Eli Lilly shares slide after report of a $2.9 billion acquisition
A market report said Eli Lilly unveiled a $2.9 billion deal tied to its Merida program, prompting investors to reassess near-term valuation and integration risks.
Healthcare’s best week since late June draws focus to a Moderna and Merck cancer trial
A rebound in healthcare equities in the week leading up to Aug. 21 traced back to trading momentum around clinical news tied to Moderna’s work and a Merck cancer study, according to a Yahoo Finance market recap.
Pfizer highlights Padcev while pushing forward PF-08634404 as part of its longer-term oncology plan
A new market report frames Pfizer’s near-term oncology momentum around Padcev, while pointing to PF-08634404 and potential label expansion efforts as catalysts the company expects to matter later.